Phys Vivas · haematological
Myelodysplastic Syndromes — Viva Defence
DCE viva defence for Myelodysplastic Syndromes.
On this page & tools
Target exams
Myelodysplastic Syndromes Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Myelodysplastic Syndromes. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
Short case
Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]
References
- [1]Nabergoj M, Bou Mjahed R, Basset V, Tsilimidos G, et al. Monocytose réactionnelle versus clonale : la leucémie myélomonocytaire chronique Rev Med Suisse, 2026.PMID 42464748
- [2]Liapis K, Papadopoulos V, Stamatiou I, Koparanis D, et al. Excess risk for cardiovascular and noncardiovascular comorbidities and multimorbidity among patients with myelodysplastic syndrome: A systematic review and meta-analysis Cancer, 2026.PMID 42464613
- [3]An W, Guo S, Wang H, Lv T, et al. The role and therapeutic potential of nanotechnology-mediated ferroptosis regulation in myelodysplastic syndromes Front Oncol, 2026.PMID 42459301
- [4]Abdulgayoom M, Gulied A, Alshurafa A, Mohamed SF, et al. Venetoclax-Integrated Conditioning Strategies Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Neoplasms: A Scoping Review of Emerging Evidence Eur J Haematol, 2026.PMID 41917774
- [5]Carraway HE, DeAngelo DJ, Wang ES, Komrokji RS, et al. Clinical strategies for leukemia management: Recommendations from the Bridging the Gaps in Hematology Oncology Consensus Conference 2025 Leuk Res, 2026.PMID 41895012
- [6]Zhang L, Ying S, Fang F, Li Q, et al. Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes Ann Med, 2026.PMID 41797681
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922